NervGen Pharma (NGEN) Fundamental Analysis: Revenue, Earnings & Valuation

5.84 / 10

Netural

Fundamental analysis rates the stock neutral at 5.8/10. Strengths include cash increase and high profit‑to‑market value, while cash‑flow growth and interest coverage are weak, dragging the overall quality. The fundamentals are fair but present notable risks.

Analysis Checks(7/10)

Revenue-MV

Value-0.26

Score3/3

Weight14.27%

1M Return10.49%

Net cash flow from operating activities per share (YoY growth rate %)

Value18.75

Score1/3

Weight2.09%

1M Return2.11%

Net profit attributable to parent company shareholders / Net profit (%)

Value100.00

Score1/3

Weight2.19%

1M Return2.26%

Profit-MV

Value-0.15

Score3/3

Weight12.68%

1M Return9.61%

Net income-Revenue

Value1.98

Score2/3

Weight7.06%

1M Return6.13%

PB-ROE

Value31.38

Score3/3

Weight11.67%

1M Return9.23%

Cash-UP

Value0.53

Score3/3

Weight8.97%

1M Return7.53%

Interest coverage ratio (EBIT / Interest expense) (%)

Value-167.64

Score1/3

Weight2.59%

1M Return2.65%

Asset-MV

Value-0.45

Score2/3

Weight17.83%

1M Return13.24%

Cash-MV

Value0.12

Score3/3

Weight20.65%

1M Return13.08%

Is NGEN fundamentally strong?

NGEN scores 5.84/10 on fundamentals and holds a Fair valuation at present. Backed by its -1457.57% ROE, 0.00% net margin, -10.97 P/E ratio, 139.16 P/B ratio, and 0.00% earnings growth, these metrics solidify its Netural investment rating.